Sarepta Therapeutics, Inc. (SRPT): who owns it and who trades it
As of Nov 16, 2026, SRPT insiders reported 2 open-market sales worth $417K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ian Michael Estepan (Chief Operating Officer), with $294K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Sarepta Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SRPT
322 funds and institutions reported SRPT shares worth $2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 18.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 18.99M | 17.99% | $341M | +29% |
| State Street Corp | 8.92M | 8.45% | $160M | +35% |
| Vanguard Portfolio Management LLC | 8.38M | 7.93% | $151M | +26% |
| Two Sigma Investments, LP | 4.60M | 4.36% | $82.6M | +0% |
| Vanguard Capital Management LLC | 4.59M | 4.35% | $82.5M | +0% |
| First Trust Advisors LP | 4.37M | 4.14% | $78.5M | +6% |
| AQR Capital Management LLC | 4.33M | 4.10% | $76.9M | -33% |
| Geode Capital Management, LLC | 2.77M | 2.63% | $49.8M | +39% |
| Erste Asset Management GmbH | 2.57M | 2.43% | $45.5M | -13% |
| Marshall Wace, LLP | 2.21M | 2.09% | $39.6M | +204% |
| Morgan Stanley | 2.20M | 2.09% | $39.6M | -15% |
| Aberdeen Group plc | 2.19M | 2.08% | $39.4M | -5% |
| Bank of America Corp | 2.06M | 1.95% | $36.9M | -4% |
| Goldman Sachs Group Inc | 2.04M | 1.93% | $36.7M | +89% |
| UBS Group AG | 1.62M | 1.54% | $29.2M | -27% |
| Federated Hermes, Inc. | 1.59M | 1.51% | $28.6M | -11% |
| Northern Trust Corp | 1.21M | 1.15% | $21.8M | +67% |
| Millennium Management LLC | 1.19M | 1.13% | $21.4M | -2% |
| T. Rowe Price Investment Management, Inc. | 1.16M | 1.10% | $20.8M | +2% |
| Citigroup Inc | 1.16M | 1.09% | $20.8M | +1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SRPT insiders reported $0 of open-market purchases and $417K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Stephen Mayo | Director | Sale | 7,239 | $17.02 | $123K | Form 4 |
| Dec 16, 2025 | Ian Michael Estepan | Chief Operating Officer | Sale | 13,187 | $22.31 | $294K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ian Michael Estepan | Chief Operating Officer | – | $294K | Dec 16, 2025 |
| Stephen Mayo | Director | – | $123K | Mar 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SRPT short interest
High short interest. 18.3% of SRPT shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went down 23%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 19.30M SRPT shares were sold short, 18.3% of the shares outstanding, down 13.6% from the report before. At the average daily volume of 2.47M shares, buying them all back would take about 7.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 19.30M | 18.27% | -14% | 2.47M | 7.8 |
| Oct 15, 2026 | 22.33M | 21.14% | -2% | 2.99M | 7.5 |
| Sep 30, 2026 | 22.78M | 21.57% | -10% | 2.64M | 8.6 |
| Sep 15, 2026 | 25.43M | 24.08% | +3% | 3.17M | 8.0 |
| Aug 31, 2026 | 24.62M | 23.31% | -9% | 2.91M | 8.5 |
| Aug 14, 2026 | 27.05M | 25.61% | -2% | 2.98M | 9.1 |
| Jul 31, 2026 | 27.57M | 26.10% | -3% | 3.14M | 8.8 |
| Jul 15, 2026 | 28.49M | 26.98% | -1% | 3.09M | 9.2 |
| Jun 30, 2026 | 28.73M | 27.22% | +14% | 5.00M | 5.8 |
| Jun 15, 2026 | 25.17M | 23.84% | +0% | 2.77M | 9.1 |
| May 29, 2026 | 25.13M | 23.80% | +0% | 2.66M | 9.4 |
| May 15, 2026 | 25.02M | 23.70% | +0% | 3.42M | 7.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded SRPT
Since Nov 17, 2024, 1 member of Congress reported 0 purchases and 1 sale of SRPT. The latest was a sale by Gilbert Ray Cisneros, Jr. on Apr 14, 2025, reported May 6, 2025.
Purchases 0Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Apr 14, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Sale | $1K–$15K | Self | May 6, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Sarepta Therapeutics company events
Sarepta Therapeutics filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 23, 2026AgreementSarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC, REGENXBIO Inc., the Trustees of the University of Pennsylvania and Catalent, Inc. entered into a settlement agreement regarding, among other matters, the resolution of pending patent infringement litigations and an appeal from inter… Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 27, 2026LeadershipThe Board of Directors of Sarepta Therapeutics, Inc. appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026. Filing
- Jun 4, 2026LeadershipSarepta Therapeutics, Inc. held its annual meeting of stockholders. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Feb 25, 2026LeadershipDouglas Ingram notified Sarepta Therapeutics, Inc. of his decision to retire as Chief Executive Officer by the end of 2026 or upon the appointment of his replacement. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 19, 2025AgreementAs previously announced, on December 10, 2025, Sarepta Therapeutics, Inc. entered into separate, privately negotiated exchange agreements with certain holders of its 1.25% Convertible Senior Notes due 2027, including the Michael A. Chambers Living Trust, an entity affiliated with Michael Chambers… Filing
- Dec 11, 2025AnnouncementThe Company issued a press release announcing the Exchange. Filing
- Dec 8, 2025LeadershipThe Board of Directors of Sarepta Therapeutics, Inc. granted equity awards to Douglas S. Ingram, the Company’s Chief Executive Officer, under the Company’s 2018 Equity Incentive Plan. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Sarepta Therapeutics financials
Famous investors that hold SRPT
4 of the 50 well-known investors we track reported holding SRPT in their latest 13F filing. The largest position is Steve Cohen's, worth $14.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 805,759 | $14.7M | 0.0% | +58% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 595,648 | $10.9M | 0.0% | +292% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 454,278 | $8.3M | 0.0% | -59% |
| Israel Englander · Millennium Management | Q3 2026 | 311,106 | $5.7M | 0.0% | -74% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SRPT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | AQR Capital Management, LLC | 13G/A | 1.3% |
| Nov 13, 2026 | AQR Capital Management, LLC | 13G/A | 1.3% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 7.0% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 7.0% |
Questions about Sarepta Therapeutics, Inc. (SRPT) stock
Who owns the most SRPT stock?
The largest reported owner of Sarepta Therapeutics, Inc. (SRPT) is BlackRock, Inc., with 18.0% of the company. In total, 322 funds and institutions reported holding SRPT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are SRPT insiders buying or selling?
In the last 12 months, SRPT insiders reported no open-market purchases and 2 sales worth $417K. The latest trade was on Mar 12, 2026. See every trade.
What is the short interest in SRPT?
As of Oct 30, 2026, 19.30M SRPT shares were sold short, 18.3% of the shares outstanding, down 13.6% from the report before. At the average daily volume of 2.47M shares, buying them all back would take about 7.8 trading days (days to cover). See the history.
Have members of Congress traded SRPT?
Yes. 1 member of Congress reported 0 purchases and 1 sale of SRPT since Nov 17, 2024. The latest was reported on May 6, 2025. See the trades.
Which famous investors hold SRPT?
4 of the 50 well-known investors we track reported SRPT in their latest 13F filing, including Steve Cohen, Ray Dalio, Jim Simons. The largest position is worth $14.7M. See all holders.
Executive pay
Sarepta Therapeutics's chief executive was paid a total of $7.8M for the year ended Dec 31, 2025, up 296% from $2M the year before. In the last 12 months, Sarepta Therapeutics's executives and directors bought no stock on the open market and sold $417K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.